After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.

While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.

Natural Products Association and Alliance for Natural Health USA petition FDA to reconsider its stance on beta-nicotinamide mononucleotide. Excluding NMN from use in supplements “adversely affects the entire dietary supplement stakeholder community,” petition says.

Cosmetic Ingredient Review’s independent expert panel finalized assessments of seven ingredients at the 6-7 March meeting, advanced two tentative safety assessments, and issued three insufficient data announcements. Propolis extract was added to the group’s 2023 priorities list while 2024 priorities remain open to public comment.

Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.

Firms removing microplastics from cosmetic products maintain European Commission’s deadline for removal across the sector is too generous. Weleda contends nine of 10 personal care products contain microplastics and 7 kg plastics a minute flushed into environment from cosmetics.